Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 6112-6118

  Zhao, Shuzhi ^a   Li, Jun ^b   Wang, Na ^a   Zheng, Bingqing ^a   Li, Tao ^a   Gu, Qing ^a   Xu, Xun ^a   Zheng, Zhi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Lishui Center Hospital   (China)

Author keywords

Diabetic retinopathy; Fenofibrate; Metabolic memory; Nuclear factor B cells; Peroxisome proliferator activated receptor a; Sirtuin 1

Indexed keywords

FENOFIBRATE; GLUCOSE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRTUIN 1; SIRT1 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL METABOLISM; DIABETIC RETINOPATHY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; AGONISTS; CELL CULTURE; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM; RETINA;

CELLS, CULTURED; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; FENOFIBRATE; GLUCOSE; HUMANS; NF-KAPPA B; PPAR ALPHA; RETINA; SIGNAL TRANSDUCTION; SIRTUIN 1; UP-REGULATION;

EID: 84940478370     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4164     Document Type: Article

References (35)

1. Lutty GA: Effects of diabetes on the eye. Invest Ophthalmol Vis Sci 54: ORSF81-87, 2013.
2. No authors listed: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342: 381-389, 2000.
3. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287: 2563-2569, 2002.
4. Ceriello A, Ihnat MA and Thorpe JE: Clinical review 2: The 'metabolic memory': is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94: 410-415, 2009.
5. Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, Jin H, He Y, Gu Q and Xu X: Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 61: 217-228, 2012.
6. Kowluru RA and Chan PS: Metabolic memory in diabetes-from in vitro oddity to in vivo problem: Role of apoptosis. Brain Res Bull 81: 297-302, 2010.
7. Kowluru RA, Chakrabarti S and Chen S: Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-kappaB) in the retina. Acta Diabetol 41: 194-199, 2004.
8. Kowluru RA, Zhong Q and Kanwar M: Metabolic memory and diabetic retinopathy: Role of inflammatory mediators in retinal pericytes. Exp Eye Res 90: 617-623, 2010.
9. Sen R and Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928, 1986.
10. Oeckinghaus A and Ghosh S: The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1: a000034, 2009.
11. DiDonato JA, Mercurio F and Karin M: NF-kappaB and the link between inflammation and cancer. Immunol Rev 246: 379-400, 2012.
12. Kowluru RA, Koppolu P, Chakrabarti S and Chen S: Diabetes-induced activation of nuclear transcriptional factor in the retina and its inhibition by antioxidants. Free Radic Res 37: 1169-1180, 2003.
13. Yu J and Auwerx J: Protein deacetylation by SIRT1: An emerging key post-translational modification in metabolic regulation. Pharmacol Res 62: 35-41, 2010.
14. Haigis MC and Sinclair DA: Mammalian sirtuins: Biological insights and disease relevance. Annu Rev Pathol 5: 253-295, 2010.
15. Baur JA: Resveratrol, sirtuins and the promise of a DR mimetic. Mech Ageing Dev 131: 261-269, 2010.
16. Cai W, Ramdas M, Zhu L, Chen X, Striker GE and Vlassara H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 109: 15888-15893, 2012.
17. Tsai KL, Huang PH, Kao CL, Leu HB, Cheng YH, Liao YW, Yang YP, Chien Y, Wang CY, Hsiao CY, et al: Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis. Biochem Pharmacol 88: 189-200, 2014.
18. Kim ES, Isoda F, Kurland I and Mobbs CV: Glucose-induced metabolic memory in Schwann cells: prevention by PPAR agonists. Endocrinology 154: 3054-3066, 2013.
19. Wang W, Bai L, Qiao H, Lu Y, Yang L, Zhang J, Lin R, Ren F, Zhang J and Ji M: The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells. Inflammation 37: 177-185, 2014.
20. Wang W, Lin Q, Lin R, Zhang J, Ren F, Zhang J, Ji M and Li Y: PPARalpha agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res 319: 1523-1533, 2013.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
22. No authors listed: The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 122: 561-568, 1995.
23. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003.
24. Ihnat MA, Thorpe JE and Ceriello A: Hypothesis: The 'metabolic memory', the new challenge of diabetes. Diabet Med 24: 582-586, 2007.
25. LeRoith D, Fonseca V and Vinik A: Metabolic memory in diabetes-focus on insulin. Diabetes Metab Res Rev 21: 85-90, 2005.
26. Baker RG, Hayden MS and Ghosh S: NF-κB, inflammation and metabolic disease. Cell Metab 13: 11-22, 2011.
27. Salminen A, Kauppinen A, Suuronen T and Kaarniranta K: SIRT1 longevity factor suppresses NF-kappaB-driven immune responses: Regulation of aging via NF-kappaB acetylation? Bioessays 30: 939-942, 2008.
28. Yao H and Rahman I: Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem Pharmacol 84: 1332-1339, 2012.
29. Xie J, Zhang X and Zhang L: Negative regulation of inflammation by SIRT1. Pharmacol Res 67: 60-67, 2013.
30. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 370: 1687-1697, 2007.
31. Ginsberg HN, Elam MB, Lovato LC III, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574, 2010.
32. Planavila A, Iglesias R, Giralt M and Villarroya F: Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation and inflammation. Cardiovasc Res 90: 276-284, 2011.
33. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, et al: Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangio-genesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57: 1394-1404, 2008.
34. Okayasu T, Tomizawa A, Suzuki K, Manaka K and Hattori Y: PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci 82: 884-891, 2008.
35. Shen W, Gao Y, Lu B, Zhang Q, Hu Y and Chen Y: Negatively regulating TLR4/NF-kappa B signaling via PPAR α in endotoxin-induced uveitis. Biochim Biophys Acta 1842: 1109-1120, 2014.